国际移植与血液净化杂志
國際移植與血液淨化雜誌
국제이식여혈액정화잡지
INTERNATIONAL JOURNAL OF TRANSPLANTATION AND HEMOPURIFICATION
2011年
4期
31-35
,共5页
寇敏%李凤英%康乃新%杨剑明
寇敏%李鳳英%康迺新%楊劍明
구민%리봉영%강내신%양검명
连续性肾脏替代%间歇性血液透析%急性肾功能衰竭%Meta分析%生存率
連續性腎髒替代%間歇性血液透析%急性腎功能衰竭%Meta分析%生存率
련속성신장체대%간헐성혈액투석%급성신공능쇠갈%Meta분석%생존솔
Continuou renal replacement therapy%Intermittent haemodialysis%Acute renal failure%Meta-analysis%Survival rate
目的 探讨连续性肾脏替代与间歇性血液透析治疗急性肾功能衰竭的生存率分析.方法 按照纳入标准搜集国内运用连续性肾脏替代和间歇性血液透析对比治疗急性肾功能衰竭的文献.使用Rev Man 5.0统计软件完成Meta分析,以SAS 8.0软件计算失安全系数.结果 按照纳入标准及排除标准,最后纳入6篇文献,包括受试患者476例进行Meta分析,其基线情况具有可比性.通过血尿素氮、肌酐及病死率指标比较差异无统计学意义(P>0.05).结论 连续性肾脏替代与间歇性血液透析均是治疗急性肾功能衰竭的有效方法,但连续性肾脏替代治疗对患者的预后及生存率比较差异无统计学意义(P>0.05).因纳入文献和样本量有限,建议进行大样本、长期随访的高质量临床试验,提供更佳循证证据.
目的 探討連續性腎髒替代與間歇性血液透析治療急性腎功能衰竭的生存率分析.方法 按照納入標準搜集國內運用連續性腎髒替代和間歇性血液透析對比治療急性腎功能衰竭的文獻.使用Rev Man 5.0統計軟件完成Meta分析,以SAS 8.0軟件計算失安全繫數.結果 按照納入標準及排除標準,最後納入6篇文獻,包括受試患者476例進行Meta分析,其基線情況具有可比性.通過血尿素氮、肌酐及病死率指標比較差異無統計學意義(P>0.05).結論 連續性腎髒替代與間歇性血液透析均是治療急性腎功能衰竭的有效方法,但連續性腎髒替代治療對患者的預後及生存率比較差異無統計學意義(P>0.05).因納入文獻和樣本量有限,建議進行大樣本、長期隨訪的高質量臨床試驗,提供更佳循證證據.
목적 탐토련속성신장체대여간헐성혈액투석치료급성신공능쇠갈적생존솔분석.방법 안조납입표준수집국내운용련속성신장체대화간헐성혈액투석대비치료급성신공능쇠갈적문헌.사용Rev Man 5.0통계연건완성Meta분석,이SAS 8.0연건계산실안전계수.결과 안조납입표준급배제표준,최후납입6편문헌,포괄수시환자476례진행Meta분석,기기선정황구유가비성.통과혈뇨소담、기항급병사솔지표비교차이무통계학의의(P>0.05).결론 련속성신장체대여간헐성혈액투석균시치료급성신공능쇠갈적유효방법,단련속성신장체대치료대환자적예후급생존솔비교차이무통계학의의(P>0.05).인납입문헌화양본량유한,건의진행대양본、장기수방적고질량림상시험,제공경가순증증거.
Objective To evaluate survival rate of Intermittent versus continuous renal replacement therapy for acute renal failure. Methods Chinese studies which meet inclusion criteria were sought, compared CRRT with IHD therapy for acute renal failure. Meta-analysis was processed by Rev Man 5.0, fail-safe number (was performed by SAS 8.0). Results Six studies involving 476 patients, met the inclusion criteria, were included in the Meta analysis. The baseline of patients' characteristics was comparable in all the studies. By comparing the three criteria, including BUN, Scr and mortality, we found that no different efficacy and mortality between CRRT and IHD. Conclusions Our data suggest that CRRT and IHD are the effective choice in the treatment of severe ARF patients. In comparison to IHD therapy, CRRT does not improve prognosis or survival in patients with ARF. Because of few studies and small samples, higher quality trials with large samples and longer following-up are proposed.